Indaptus Therapeutics News and Activities

View the org chart displaying its 10 main executives

Most searched biographies at Indaptus Therapeutics

• Mark Gilbert, Director
• Hila Karah, Director
• Jerome Jabbour, Director

Popular executive movements at Indaptus Therapeutics

• Walt Linscott, Chief Operating Officer, has left the company  (posted on June 8 2026).
• David Lazar, Director, has left the company  (posted on June 8 2026).
• Avraham Ben-Tzvi, Director, has left the company  (posted on June 8 2026).

Click here to view some more movements at Indaptus Therapeutics

Create your alert
to follow the executive moves at Indaptus Therapeutics.

Indaptus Therapeutics has 2,417 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Tissium has just announced a $68 Million fundraising (posted on June 29 2026).
• Oblenio Bio has just announced a $62 Million fundraising (posted on June 26 2026).
• Agilent Technologies has acquired Biocare Medical (posted on June 26 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by Indaptus Therapeutics

• Intec Pharma Announces New Research Collaboration Agreement with MSD | Intec Pharma
• Intec Pharma to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit | Intec Pharma
• Intec Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference | Intec Pharma
• Press Releases | Intec Pharma
• Intec Pharma Announces Pricing of $4.9 Million Registered Direct Offering | Intec Pharma
• Intec Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Intec Pharma
• Intec Pharma to Present at Jefferies Virtual Healthcare Conference | Intec Pharma
• Intec Pharma Reports First Quarter 2020 Financial Results and Provides Corporate Update | Intec Pharma
• Intec Pharma Announces $5.0 Million Registered Direct Offering | Intec Pharma
• Intec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate Update | Intec Pharma
• View more press releases Close

Social media about Indaptus Therapeutics

• Indaptus Therapeutics on Wikipedia, Google News & Yahoo Finance
• Indaptus Therapeutics on LinkedIn, X (Twitter) & YouTube